Danish company vies with US drugmaker for control of Metsera as they seek edge in growing market for weight-loss drugs

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond weight loss for a treatment that has disappointed investors.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.

Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was invited to the “Boundless Care, New Beginnings” 2025 Health Ecosystem Partner Alliance Summit and New Product Launch Ceremony,

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market. WHAT IS METSERA? Metsera is a New York-based clinical-stage biotech firm focused on developing treatments for obesity and metabolic diseases.

The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.

(Reuters) -Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for U.S. government-backed insurance programs and cash payers.